Tabula Rasa HealthCare company profile: involvement in pharmacogenomic and personalized medicine research-Reference-Cited by-同舟云学术

Tabula Rasa HealthCare company profile: involvement in pharmacogenomic and personalized medicine research

Published:2021-08 Issue:12 Volume:22 Page:731-735
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Matos Adriana¹,Dow Pamela²,Bingham Jennifer M¹^ORCID,Michaud Veronique²³^ORCID,Lesko Lawrence J⁴^ORCID,Knowlton Calvin H⁵,Turgeon Jacques²³^ORCID

Affiliation:

1. Office of Translational Research & Residency Programs, Tabula Rasa HealthCare, Moorestown, NJ 08057, USA

2. Precision Pharmacotherapy Research & Development Institute, Tabula Rasa HealthCare, Orlando, FL 32827, USA

3. Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, H3C 3J7, Canada

4. Center for Pharmacometrics & Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL 32827, USA

5. Corporate Office & Headquarters, Tabula Rasa HealthCare, Moorestown, NJ 08057, USA

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2021-0085

Reference34 articles.

1. Toleos A. Press release: millions of older Americans harmed by too many medications. https://lowninstitute.org/press-release-millions-of-older-americans-harmed-by-too-many-medications/

2. Garber J. Lown Institute. Eliminating medication overload: a national action plan. (2020). https://lowninstitute.org/wp-content/uploads/2020/01/lown-eliminating-medication-overload-web.pdf

3. Lown Institute. Garber J, Brownlee S.Medication overload: America’s other drug problem. (2019). https://lowninstitute.org/reports/medication-overload-americas-other-drug-problem/

4. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing

5. Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy